Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,187.67 -0.03 (-0.00%) Dow
39,056.39 +172.13 (+0.44%) Nasdaq
16,302.76 -29.80 (-0.18%) Bitcoin USD
61,380.76 -1,207.54 (-1.93%) CMC Crypto 200
1,304.69 +10.02 (+0.77%)
Beyond Air, Inc. (XAIR)
After hours:
| Previous close | 1.2900 |
| Open | 1.2900 |
| Bid | 1.2800 x 400 |
| Ask | 1.3100 x 500 |
| Day's range | 1.2400 - 1.3900 |
| 52-week range | 1.0600 - 6.3600 |
| Volume | |
| Avg. volume | 300,845 |
| Market cap | 59.212M |
| Beta (5Y monthly) | -0.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.1300 |
| Earnings date | 20 Jun 2024 - 24 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.67 |
GlobeNewswireBeyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
Company to host an event featuring key opinion leaders (KOLs) on Friday, May 31st in Chicago to highlight the ongoing clinical development of UNOHAMILTON, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced being selected to present on the clinical development program of its Ultra-High Concentration Nitric Oxide (UNO) at the upcoming A
- GlobeNewswire
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
GARDEN CITY, N.Y., March 20, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that it has entered into a securities purchase ag
- GlobeNewswire
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024
Commercial demand for LungFit® PH increasing; manufacturing of upgraded devices is ramping up to meet growing demand PMA supplement for the expansion of LungFit PH label to include cardiac surgery accepted for filing and under substantive review by the FDA U.S. pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway; trial will extend over two seasons; the pivotal study remains on track for Winter 2025/26 Phase 1 Study evaluating Beyond Cancer’s ultra-high concent
